Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines

The diagnostic and treatment methods of multiple myeloma (MM) have been rapidly evolving owing to advances in imaging techniques and new therapeutic agents. Imaging has begun to play an important role in the management of MM, and international guidelines are frequently updated. Since the publication of 2015 International Myeloma Working Group (IMWG) criteria for the diagnosis of MM, whole-body magnetic resonance imaging (MRI) or low-dose whole-body computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/CT have entered the mainstream as diagnostic and treatment response assessment tools. The 2019 IMWG guidelines also provide imaging recommendations for various clinical settings. Accordingly, radiologists have become a key component of MM management. In this review, we provide an overview of updates in the MM field with an emphasis on imaging modalities.

[1]  Jeong Hyun Lee,et al.  Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response , 2020, Cancer Imaging.

[2]  H. Goldschmidt,et al.  International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. , 2019, The Lancet. Oncology.

[3]  M. Mohty,et al.  Current status of autologous stem cell transplantation for multiple myeloma , 2019, Blood Cancer Journal.

[4]  Kyu-Won Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[5]  V. Goh,et al.  Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. , 2018, Critical reviews in oncology/hematology.

[6]  R. Greil,et al.  The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe , 2018, Expert review of hematology.

[7]  Nickolas Papanikolaou,et al.  Functional and molecular MRI of the bone marrow in multiple myeloma. , 2018, The British journal of radiology.

[8]  T. Spektor,et al.  Monitoring multiple myeloma. , 2017, Clinical advances in hematology & oncology : H&O.

[9]  F. Gherlinzoni,et al.  Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. , 2017, Clinical radiology.

[10]  H. Goldschmidt,et al.  Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group , 2017, Blood Cancer Journal.

[11]  Vicky Goh,et al.  Guidelines for the use of imaging in the management of patients with myeloma , 2017, British journal of haematology.

[12]  J. Oldan,et al.  PET/MR Imaging of Multiple Myeloma. , 2017, Magnetic resonance imaging clinics of North America.

[13]  Bart Barlogie,et al.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.

[14]  S. Raza,et al.  The Critical Role of Imaging in the Management of Multiple Myeloma , 2017, Current Hematologic Malignancy Reports.

[15]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  M. Dimopoulos,et al.  Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. , 2017, Radiology.

[17]  H. Goldschmidt,et al.  Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group , 2016 .

[18]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[19]  T. Plesner,et al.  Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.

[20]  K. Verstraete,et al.  Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. , 2016, European journal of radiology.

[21]  F. Cretti,et al.  Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM) , 2016, La radiologia medica.

[22]  S. Ailawadhi The Changing Face of Multiple Myeloma , 2015 .

[23]  Jian Hou,et al.  Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Verstraete,et al.  The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma , 2014, European Radiology.

[25]  G. Morgan,et al.  The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma , 2014, Expert review of hematology.

[26]  R. Eslick,et al.  Multiple myeloma: from diagnosis to treatment. , 2013, Australian family physician.

[27]  K. Verstraete,et al.  Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. , 2013, European journal of radiology.

[28]  G. Morgan,et al.  Assessing response of myeloma bone disease with diffusion-weighted MRI. , 2012, The British journal of radiology.

[29]  M. Dimopoulos,et al.  Advances in imaging and the management of myeloma bone disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Tobias Bäuerle,et al.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[33]  B. Barlogie,et al.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Reiser,et al.  Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.

[35]  M. Dimopoulos,et al.  Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. , 1992, Radiology.

[36]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.

[37]  N. Pandit-Taskar Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. , 2018, Seminars in hematology.

[38]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[39]  M. Dimopoulos,et al.  The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[40]  Jun Zhang,et al.  A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease--which is best? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[41]  M. Dreyling,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  P. Greipp,et al.  Biology and treatment of myeloma. , 1996, Current opinion in oncology.

[43]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[44]  G. Edelstyn,et al.  The radiological demonstration of osseous metastases. Experimental observations. , 1967, Clinical radiology.

[45]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.